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Abstract
Permanent vision loss is one of the most serious complications of giant cell arteritis (GCA) and therefore prompt diagnosis 
is paramount. However, diagnosis of GCA remains challenging due to its frequently non-specific presentation. Our aim was 
to identify differences in the characteristics of GCA patients with, and without, current visual symptoms. A cross-sectional 
survey was mailed to patients with a GCA Read code entered in their GP electronic medical record. Responders were cat-
egorised as those currently reporting a visual symptom or not. We compared general and GCA-specific characteristics in 
these two groups. The association of diagnostic delay with subsequent experience of visual symptoms was examined using 
unadjusted and adjusted linear regression analysis. 318 GCA patients responded to the survey (59.6%). Responders were 
predominantly female (69.8%), with a mean age of 73.7 years (SD 8.2). 28% reported current visual symptoms. There was no 
statistically significant difference in the general characteristics between those with and without visual symptoms. Of GCA-
specific characteristics, pre-GCA diagnosis of diplopia (p = 0.018), temporary (p ≤ 0.001) or permanent visual problems 
(p = 0.001) and hoarseness (p = 0.004) were more common among those reporting current visual symptoms. There was no 
association between the extent of diagnostic delay and reporting of current visual symptoms. Though we found few charac-
teristics to distinguish between GCA patients with or without current visual symptoms, diagnostic delay was not associated 
with current visual symptoms. Our findings highlighted the continued difficulty for clinicians to identify GCA patients at 
the highest risk of visual complications.
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Introduction
Giant cell arteritis (GCA) is the commonest medium- 
and large-vessel vasculitis of older people, with a peak 
incidence of 7.4 per 10,000 person years in women aged 
70–79 years [1]. This inflammatory condition has a par-
ticular predilection for certain arteries, affecting the super-
ficial temporal and posterior ciliary arteries as well as 
others including the aorta and its proximal branches [2]. 
Inflammation causes local vascular ischaemia and cytokine 
release [3], which can result in ischaemic eye manifesta-
tions including anterior ischaemic optic neuropathy or reti-
nal artery occlusion. Symptoms experienced may include 
diplopia, amaurosis fugax and transient or permanent vis-
ual loss, one of the most serious consequences of GCA [4, 
5]. Early initiation of high-dose corticosteroids (initially 
40–60 mg of prednisone equivalent) at onset of symptoms 
among patients with suspected GCA is the mainstay of 
treatment, reducing the risk of visual complications, visual 
loss and other serious outcomes such as stroke or cerebral 
artery dissection [6].
Despite the importance of patients receiving a prompt 
diagnosis of GCA in primary care, this remains difficult 
to achieve. The non-specific nature of many GCA symp-
toms can lead to patients not consulting, or the general 
practitioner (GP) associating these symptoms or features, 
of which many are commonly seen in primary care (e.g. 
tiredness, fever and weight loss), with conditions other 
than GCA. GPs may also over-rely on a “classic” GCA 
presentation (e.g. temporal headache, scalp tenderness 
and jaw claudication) before considering a GCA diagno-
sis, although these “classic” symptoms are by no means 
universal in GCA [7]. A recent clinical review by van der 
Geest et al. classified GCA as a clinically and immunologi-
cally heterogeneous autoimmune disease, dividing it into 
three subsets: (i) systemic inflammation, (ii) vasculitis of 
large systemic arteries and (iii) polymyalgia rheumatica 
[8]. Related to the specific outcome of visual loss, studies 
have suggested that the risk of visual loss is higher in GCA 
patients with symptoms such as jaw claudication and in 
patients who do not have the typical temporal headache 
[2]. In view of such variability, there is an increasing inter-
est to determine whether clinically important GCA patient 
subsets, such as those who do develop visual complica-
tions, can be identified by distinct patient characteristics.
Improved identification of patients with GCA will 
reduce persistent diagnostic delay which continues to 
be a significant problem [7]. A systematic review and 
meta-analysis identified an average of 8-week diagnostic 
delay for patients presenting with ‘cranial’ symptoms and 
18 weeks for those with ‘non-cranial’ symptoms [9]. In 
view of the severe ophthalmic complications attributed to 
delayed diagnosis and treatment of GCA, there has been 
increasing research to reduce these delays. This includes 
the introduction of fast-track clinics to support the diag-
nosis of GCA, which have been suggested to be associ-
ated with reduced incidence of sight loss [10]. However, 
such clinics require GPs to be able to accurately identify 
patients requiring referral and emphasises the need to bet-
ter understand different GCA patient subsets, especially 
among GCA patients at higher risk of visual symptoms 
compared to those without.
The aim of this study was to characterise UK primary 
care patients with prevalent GCA. Our specific objectives 
were i) to compare the general and GCA-specific charac-
teristics of those currently reporting visual symptoms and 
those without visual symptoms and ii) to examine the role 
of diagnostic delay prior to GCA diagnosis on experience of 
current visual symptoms.
Materials and methods
Study design and population
A self-completion questionnaire was used to collect cross-
sectional data from patients with GCA. A power calculation 
determined that the invitation of approximately 500 patients 
with GCA would provide the minimum 300 patients required 
to estimate diagnostic delay in this patient group. Adults 
aged 50 years or older registered to general practices from 
several regions of England (Clinical Research Network 
(CRN) areas of: West Midlands (North), Eastern and North 
Thames) and with any Read coded diagnosis of GCA in 
the 3 years before the survey were invited to participate in 
the study. Recruitment occurred from January 2015 to Sep-
tember 2016. Patients identified with GCA by the National 
Institute for Health Research (NIHR) CRNs were mailed an 
invitation pack, which included a patient information sheet, 
survey questionnaire and consent form. This study was given 
ethical approval by the West Midlands—South Birmingham 
Local Research Ethics Committee (Ref no: 14/WM/1205) 
and all patients provided written informed consent.
Data collection
Data were collected through a self-report postal survey. 
Socioeconomic data collected included age, gender, body 
mass index [BMI, from self-report height and weight), level 
of deprivation (using Indices of Multiple Deprivation (IMD 
[11])], smoking status and medical comorbidities. Data from 
a range of GCA-specific characteristics were also collected, 
including GCA-related symptoms experienced prior to GCA 
diagnosis, extent of self-reported delay in receiving a GCA 
diagnosis, age at diagnosis, type of health-care professional 
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who diagnosed GCA and doses of prednisolone treatment 
given when commenced and now currently being taken. 
Though the questionnaire was not piloted, it was quality 
assessed internally and included several validated question-
naires, including the Short-Form 12 (SF-12) to measure 
general physical and mental health [12], the Generalized 
Anxiety Disorder 7-item (GAD-7) scale [13] and Patient 
Health Questionnaire (PHQ9) [14] to assess the presence of 
anxiety and depression, respectively, and finally the Visual 
Function Questionnaire-14 (VF-14) as a method of assessing 
the quality of visual function [15].
Statistical analysis
Survey responders were stratified into two groups: (i) GCA 
patients with current visual symptoms and (ii) GCA patients 
without current visual symptoms. The visual symptoms 
group was defined as those currently reporting having at 
least one of three visual symptoms attributed to their GCA: 
double vision, temporary vision problems and permanent 
vision problems.
The general and GCA-specific characteristics of the 
study sample were initially summarised using descriptive 
statistics. The mean age [with standard deviation (SD)] 
and gender ratio were reported, BMI was categorised into 
three groups (< 24.9 kg/m2 healthy weight, 25.0–29.9 kg/
m2 overweight, > 30.0 kg/m2 obese), as was IMD (the 20% 
least deprived, mid-deprived and 20% most deprived). 
Smoking status classified responders into those who had 
never smoked, previously smoked or were current smokers. 
Responders reported whether they had previously received a 
diagnosis for one of the listed comorbidities (hypertension, 
hyperlipidaemia, polymyalgia rheumatica, diabetes, stroke, 
cancer, cataracts and glaucoma). The presence of anxiety 
and depression was determined by a score > 10 on the GAD7 
or PHQ-9 measures, respectively. The VF-14 is scored on a 
scale of 0 (not capable) to 100 (perfectly capable) related to 
aspects of daily living affected by vision.
With regard to GCA-specific characteristics, mean age 
at diagnosis was reported and using this, disease duration 
was calculated [median, interquartile range (IQR)]. The 
prevalence of any of 18 potential GCA symptoms could be 
reported by survey responders (headache/head pain, tired-
ness/fatigue, temporary vision problems, scalp tenderness, 
shoulder pain or stiffness, pain or difficulty chewing, ear 
pain, loss of appetite, pain in lower body when walking, 
double vision, high temperature, hip pain or stiffness, tooth-
ache, hoarseness, weight loss, pain in upper body when 
walking, dry cough and permanent vision problems) and 
the patients’ historical and current prednisolone use were 
reported as absolute values and percentages. Use of predni-
solone was further described by asking patients to record the 
starting dose and current daily doses. Both were categorised 
into three groups, starting doses by < 40 mg, 40–60 mg 
or > 60 mg and current prednisolone daily dose by those 
taking < 7.5 mg, 7.5–10 mg, or > 10 mg. Three aspects of 
delay were measured: (i) the time taken for the patient to 
consult their doctor (consultation delay), (ii) time between 
first consultation and GCA diagnosis (diagnostic delay) and 
(iii) the total time between symptom onset and GCA diag-
nosis (total delay). Each delay category was reported as the 
median (IQR) number of days of delay.
Comparisons of data between GCA patients with and 
without current visual symptoms were made using t test, 
Mann–Whitney U test or Fisher exact test as appropriate. 
Given that delay data were skewed, multivariable linear 
regression analysis with bootstrapping was used to exam-
ine the association between the number of days of delay for 
each delay category experienced (consultation, diagnostic 
and total) and the presence of visual symptoms among GCA 
patients, as compared to GCA patients without visual symp-
toms. We constructed bias-corrected and accelerated (BCa) 
bootstrapped 95% confidence intervals for the regression 
coefficients as these are robust to non-normality [16]. The 
analysis was initially unadjusted, followed by adjustment for 
age, gender and deprivation. Age, as a continuous predictor, 
had a linear relationship with the delay interval, and not a 
non-linear effect such as age squared.
Results
Of the 534 patients with GCA who were mailed a ques-
tionnaire, 318 responded (adjusted response rate of 59.6%) 
from a total of 130 general practices. The mean age (SD) of 
responders was 73.7 (8.2) years, 222 patients (69.8%) were 
female, 79 patients (24.7%) were obese and 151 patients 
(47.6%) had never smoked. Of responders, 90 (28.3%) 
reported a current visual symptom, with just over half 
(55.0%) of these being new cases who reported visual symp-
toms developing only after diagnosis. 228 survey respond-
ers reported no current visual symptoms at the time of the 
survey (71.7%).
General characteristics
There was no significant difference between the demo-
graphic factors (age, gender, deprivation status, BMI and 
smoking status) of GCA patients with or without current 
visual symptoms. Of the self-report comorbidities, anxiety 
(p = 0.023) was more frequent in those with current visual 
symptoms (Table 1). GCA patients without current visual 
symptoms had higher (better) mean SF-12 PCS score of 
40.9 (SD 12.3, p = 0.0001) and mean SF-12 MCS score of 
47.1 (SD 11.1, p = 0.028) as compared to patients with cur-
rent GCA visual symptoms. GCA patients without visual 
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symptoms also had a higher (better visual function) mean 
VF-14 score (Mean 86.9, SD 17.6) as compared to the other 
group (Mean 71.9, SD 25.9) and this was statistically sig-
nificant (p = 0.000) (Table 2).
GCA‑specific characteristics
There was no difference in the age at which GCA patients 
were diagnosed or the disease duration for those with or 
without current visual symptoms. The three commonest 
symptoms experienced by GCA patients with current visual 
symptoms prior to their diagnosis were headache (82.2%), 
tiredness/fatigue (63.3%) and temporary vision problems 
(52.2%), whereas among GCA patients without current 
visual symptoms, the commonest symptoms were headache 
(87.3%), scalp tenderness (59.7%) and tiredness/fatigue 
(57.8%). Comparing groups of GCA patients with visual 
symptoms to those without, the proportions of patients 
with hoarseness, double vision, temporary visual problems 
and permanent visual problems were significantly higher 
for those with current visual symptoms. Comparing GCA 
patients with current visual symptoms to those without, a 
higher proportion of patients in the former group (25.0%) 
than the latter (12.7%) had GCA first diagnosed by an oph-
thalmologist (p = 0.010) (Table 2).
Delays in receiving GCA diagnosis
Of the total survey responders, the median number of days 
of delay in seeking health care (consultation delay) was 14 
(IQR 7, 42), diagnostic delay was 14 (IQR 4, 35) and total 
days of delay was 35 (IQR 18, 91). Using linear regression 
analyses with bootstrapping, adjusted for age, gender and 
deprivation, we found no significant difference between the 
number of days of consultation [− 1.19 (− 29.85, 27.46)], 
diagnostic [− 6.07 (− 28.23, 16.10)] or total delay [− 2.29 
(− 50.97. 46.40)] experienced by GCA patients with a cur-
rent visual symptom, compared to those with no current 
visual symptom (Table 3).
Table 1  Baseline characteristics 
of patients with GCA who are 
currently experiencing visual 
symptoms and those without 
current visual symptoms
*Significance and p ≤ 0.05
GCA with current visual 
symptoms (N = 90)
GCA without current visual 
symptoms (N = 228)
p value
Mean age (SD) 72.6 (8.4) 74.1 (8.0) 0.131
Gender (n,  %)
 Male 26 (28.9) 70 (30.7) 0.788
 Female 64 (71.1) 158 (69.3)
Deprivation status (n,  %)
 20% least deprived 17 (18.9) 46 (20.4) 0.895
 60% middle 56 (62.2) 133 (59.2)
 20% most deprived 17 (18.9) 46 (20.4)
BMI (n,  %)
 Healthy weight (< 24.9 kg/m2) 27 (32.9) 93 (43.5) 0.146
 Overweight (25.0–29.9 kg/m2) 29 (35.4) 74 (34.6)
 Obese (> 30.0 kg/m2) 26 (31.7) 47 (21.9)
Smoking status (n,  %)
 Never smoked 42 (47.2) 108 (47.8) 0.796
 Previous smoker 40 (44.9) 105 (46.4)
 Current smoker 7 (7.9) 13 (5.8)
Comorbidities at baseline (n,  %)
 Hypertension 53 (58.9) 111 (48.9) 0.135
 Hyperlipidaemia 35 (38.9) 93 (41.0) 0.800
 Polymyalgia rheumatic 26 (28.9) 71 (31.3) 0.787
 Depression 25 (32.5) 49 (24.6) 0.187
 Anxiety 24 (30.8) 38 (18.3) 0.023*
 Diabetes 23 (25.6) 36 (15.9) 0.055
 Stroke 9 (10.0) 19 (8.4) 0.666
 Cancer 7 (7.8) 25 (11.0) 0.535
 Cataracts 29 (32.2) 70 (30.8) 0.893
 Glaucoma 8 (8.9) 18 (7.9) 0.821
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Discussion
Our cross-sectional analysis of patients with prevalent 
GCA from primary care has identified that approximately 
a quarter of our sample were currently experiencing some 
form of visual symptom, and of these, approximately 
half had had no visual symptoms before their diagnosis 
of GCA. There were few significant differences between 
patients reporting current visual symptoms and those 
without. As would be expected, patients with current 
visual symptoms reported more visual symptoms prior to 
GCA diagnosis, were more likely to have had their GCA 
Table 2  GCA-specific 
characteristics of patients with 
and without visual symptoms
*Significance and p ≤ 0.05
GCA with current visual 
symptoms (N = 90)
GCA without current 
visual symptoms (N = 228)
p value
Age at diagnosis (mean; SD) 69.6 (8.5) 71.5 (8.1) 0.072
Disease duration (median years; IQR) 2.7 (1.1, 3.2) 2.1 (1.2, 3.1) 0.815
Symptoms before GCA diagnosis (n,  %)
 Headache/head pain 74 (82.2) 199 (87.3) 0.284
 Tiredness/fatigue 57 (63.3) 132 (57.8) 0.447
 Temporary vision problems 47 (52.2) 70 (30.7) 0.000*
 Scalp tenderness 44 (48.9) 136 (59.7) 0.102
 Shoulder pain or stiffness 41 (45.6) 105 (46.1) 1.000
 Pain or difficulty chewing 39 (43.3) 104 (45.6) 0.803
 Ear pain 30 (33.3) 53 (23.3) 0.088
 Loss of appetite 28 (31.1) 54 (23.7) 0.200
 Pain in lower body when walking 27 (30.0) 65 (28.5) 0.785
 Double vision 22 (24.4) 30 (13.2) 0.018*
 High temperature 21 (23.3) 32 (14.0) 0.065
 Hip pain or stiffness 19 (21.1) 58 (25.4) 0.469
 Toothache 18 (20.0) 41 (18.0) 0.749
 Hoarseness 17 (18.9) 16 (7.0) 0.004*
 Weight loss 16 (17.8) 48 (21.1) 0.642
 Pain in upper body when walking 15 (16.7) 30 (13.2) 0.475
 Dry cough 13 (14.4) 34 (14.9) 1.000
 Permanent vision problems 11 (12.2) 6 (2.6) 0.001*
Who diagnosed GCA (n,  %)
 GP 56 (63.6) 163 (71.5) 0.177
 Rheumatologist 38 (43.2) 91 (39.9) 0.611
 Ophthalmologists 22 (25.0) 29 (12.7) 0.010*
 Geriatrician 1 (1.1) 2 (0.8) 1.000
 Others 15 (17.1) 34 (14.9) 0.729
Prednisolone use
 Ever taken prednisolone? 87 (97.8) 217 (95.6) 0.520
 Still taking prednisolone? 64 (71.9) 148 (68.5) 0.587
 Current prednisolone daily dose
  < 7.5 mg 37 (62.7) 90 (65.2) 0.260
  On maintenance 7.5–10 mg 7 (11.9) 25 (18.1)
  > 10 mg 15 (25.4) 23 (16.7)
 Prednisolone starting dose
  < 40 mg 21 (26.9) 48 (24.6) 0.488
  40–60 mg 51 (65.4) 138 (70.8)
  > 60 mg 6 (7.7) 9 (4.6)
VF-14 (mean; SD) 71.9 (25.9) 86.9 (17.6) 0.000*
SF-12 PCS score (mean; SD) 34.6 (10.8) 40.9 (12.3) 0.0001*
SF-12 MCS score (mean; SD) 43.8 (11.4) 47.1 (11.1) 0.028*
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diagnosed by an ophthalmologist and reported poorer vis-
ual function at the time of the survey. Importantly, GCA 
patients with current visual symptoms had not taken any 
longer to consult their GP and did not experience a greater 
delay in receiving a diagnosis as compared to those with-
out visual symptoms. However, despite similar starting 
and current prednisolone doses between the two groups, 
GCA patients with current visual symptoms reported sig-
nificantly more anxiety and poorer general physical and 
mental health. Finally, of the many non-vision-related 
symptoms reported prior to GCA diagnosis, only hoarse-
ness was more common in GCA patients with current 
visual symptoms.
We found the prevalence of current visual symptoms in 
our sample to be similar to several other GCA studies. Pop-
ulation-based cohort studies performed by Singh et al. in the 
USA and Salvarani et al. in Italy reported 23% and 30.1% of 
patients with visual changes, respectively [17, 18]. Another 
prospective study of 174 patients showed the occurrence 
of visual ischaemic manifestations among 28% of patients, 
with permanent visual loss in 13% of them [19]. In patients 
with biopsy-proven GCA, Gonzalez-Gay et al. performed a 
retrospective study at a single reference hospital in Spain, 
which showed that 26.1% had visual ischaemic complica-
tions and 14.9% had irreversible blindness [20]. However, 
lower rates of visual complications have also been reported 
(12–15%) [21, 22]. Any discrepancy with our findings could 
be explained by the differences in the study design and in 
the case mix of included patients. Our reported proportion 
of visual symptoms could also be an underestimation, as 
samples from these previous studies were identified through 
hospital episodes and also visual complications were not 
well defined in many studies, causing difficulties in accurate 
case ascertainment.
Our study showed that GCA patients with current visual 
symptoms experienced significantly more anxiety and poorer 
general physical and mental health at baseline, assessed by 
SF-12 summary scores. Though a qualitative study per-
formed in the UK also found that anxiety about future visual 
loss was an important concern of GCA patients [23], this 
is in contrast to other studies. Jobard et al. and Kupersmith 
et al. found that GCA visual complications did not have 
any major impact on health-related quality of life (QoL), as 
assessed using the SF-36 score [24, 25]. However, neither of 
the aforementioned studies distinguished between patients 
with and without visual symptoms.
As we appreciate that vision ranks as the number one 
concern among patients with GCA [24], our study used the 
VF-14 [26] as a measure of visual function among GCA 
subjects. Expectedly, GCA patients with current visual 
symptoms had lower (worse) VF-14 score than those without 
visual symptoms. However, as context for the visual “situ-
ation” of our current visual symptom group, Valderas et al. 
found that for a patient with a VF-14 of 71 (comparable 
to our group), this would correspond to a visual function 
allowing the patient to be ‘doing fine handwork’, ‘watch-
ing TV’ or ‘recognising people’ without difficulty, but with 
some difficulty ‘reading small print’ and unable to ‘drive at 
night’ [27]. However, as the VF-14 has only been validated 
in ophthalmological conditions such as cataract, glaucoma, 
corneal transplants, keratoconus and dry eye disease, such 
comparisons should be interpreted with caution [26].
The multitude of symptoms experienced prior to GCA 
diagnosis in our sample was extensive. However, the only 
non-vision-related symptom to be reported prior to GCA 
diagnosis and to distinguish those patients with or without 
current visual symptoms was hoarseness. Hoarseness has 
only previously been reported infrequently in case reports 
Table 3  Association between GCA patients with or without visual symptoms and the difference in the number of days of delay experienced in 
receiving their diagnosis of GCA 
*Adjusted by age, gender and deprivation
Median days of delay (IQR) Linear regression analysis
Unadjusted mean difference in days of 
delay (95% CI)
Adjusted mean difference 
in days of delay (95% 
CI)*
Consultation delay
 No visual symptoms 14.0 (7.0, 58.4) Ref Ref
 Visual symptoms 14.0 (5.0, 30.4) − 1.37 (− 26.2, 23.46) − 1.19 (− 29.85, 27.46)
Diagnostic delay
 No visual symptoms 14.0 (4.0, 42.0) Ref Ref
 Visual symptoms 14.0 (4.0, 30.4) − 7.13 (− 30.33, 16.08) − 6.07 (− 28.23, 16.10)
Total delay
 No visual symptoms 36.2 (19.0, 93.0) Ref Ref
 Visual symptoms 35.0 (16.0, 65.8) − 3.37 (− 49.47, 42.72) − 2.29 (− 50.97, 46.40)
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or case series [28, 29]. Our findings are in contrast to previ-
ous research which showed that patients with visual symp-
toms were less likely to have headaches, fever and a palpa-
ble tender temporal artery (not recorded by our study), and 
more likely to have jaw claudication [17, 30]. Many previ-
ous studies have also found an inverse relationship between 
fever or high temperature and the development of ischaemic 
complications [31], and that lower inflammatory responses 
occurred in GCA patients with visual symptoms as com-
pared to those without visual symptoms [19]. This could 
be explained by differences in consultation patterns, in that 
those with fever or significant systemic symptoms may be 
more likely to consult or receive glucocorticoid treatment 
and hence be at lower risk of visual complications.
Due to the non-specific symptoms of GCA, diagnos-
tic delay is common [9], but previous research has shown 
conflicting evidence of association of diagnostic delays 
and visual loss. Ezeonyeji et al. highlighted that diagnos-
tic delay is associated with increased risk of irreversible 
visual loss among patients with GCA [7], but Gonzalez-
Gay et al. showed no association of the length of delay of 
GCA diagnosis with the risks of visual manifestations and 
permanent visual loss [20]. However, delay is multifaceted 
and our work has examined both delays which are predomi-
nately related to the actions of patients (consultation delay) 
and to those actions of the clinician (diagnostic delay). We 
found no significant difference in reported consultation or 
diagnostic delay between GCA patients with current visual 
symptoms versus those without visual symptoms.
Strengths and limitations
The strength of our study is the provision of new information 
on general and GCA-specific characteristics of an important 
subset of patients with GCA for which large datasets are 
limited. This study, which recruited patients from several 
regions of England, recorded extensive information regard-
ing symptoms, both before GCA diagnosis and several years 
after. This also separates out consultation and diagnostic 
delay.
Limitations of our work include the use of a cross-sec-
tional, self-report mailed survey, as such a design may have 
introduced both selection and recall bias. Regarding selec-
tion bias, recruitment directly through the CRNs means 
we were unable to determine which patients were unwill-
ing to take part and whether these are a different subset of 
patients with GCA, for example, such patients could have 
included those with poor vision and therefore have been 
limited in their ability to complete a postal questionnaire 
or simply unwilling. Regarding recall bias, patients may 
have had problems answering questions accurately which 
related to previous events several years prior, i.e. symptoms 
at the point of a diagnosis. However, this design was the 
most practical for the collection of detailed data from elderly 
patients (or their proxies) across several different geographi-
cal areas, and delay and symptom prevalence data reflect 
previous research, providing confidence in the generalisabil-
ity of our results. A further limitation relates to the cause of 
symptoms. Though our questionnaire requested the report-
ing of symptoms in the context of “being caused by your 
GCA”, there is a potential that these were caused by other 
comorbidities or even a consequence of GCA treatment; oral 
glucocorticoid treatment can also affect vision via several 
mechanisms including accelerated cataract formation and 
changes in blood glucose levels [32]. Therefore, this self-
reporting of symptoms could have been due to heterogene-
ous aetiologies and there is the potential for misclassification 
of outcome. Finally, due to the rarity of GCA and therefore 
a smaller sample, we were required to group several visual 
symptoms together for analysis and were unable to strat-
ify the ‘current visual symptoms’ group further into those 
with symptoms before or after GCA diagnosis. Despite our 
inability to tease out these differences, our work remains a 
much needed comparison of the visual symptoms subgroup 
of GCA patients.
In conclusion, visual symptoms remain a serious and 
common problem among patients with GCA, both before and 
several years after diagnosis. Early, appropriate treatment is 
important as GCA-related symptoms are preventable and if 
GCA-related visual symptoms are present, then urgent treat-
ment and referral to ophthalmology is essential to prevent 
progression and ultimately complete blindness. However, we 
found little to distinguish this subset of GCA patients from 
those who did not report current visual symptoms, high-
lighting the continued difficulty for health-care professionals 
(and GPs in particular) to identify these patients promptly, 
even those with serious symptoms. Though both patient and 
health-care-related delay persists, this appears to be less than 
previously reported and visual symptoms may not be related 
to the extent of the delay experienced. Longitudinal analysis 
on this topic is needed to fully characterise GCA patients 
prior to or at disease onset, to reduce diagnostic and subse-
quently treatment delays.
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